Navigation Links
Need microRNA processing? Get Smad
Date:6/11/2008

BOSTON (embargoed until June 11, 2008, 1:00 p.m. ET) Researchers at Tufts University School of Medicine and Tufts Medical Center have found that Smad proteins regulate microRNA (miRNA) processing. Understanding the role of Smad proteins enables researchers to investigate abnormal miRNA processing which is a contributing factor in development of cardiovascular disorders and cancer. The study was published online today in Nature.

"We found that Smad proteins, the signal carriers of a group of proteins that help regulate cells, promote the processing of a subset of microRNA, including miR-21. Smad proteins control the processing of miRNA from a primary copy of RNA (pri-miRNA) to precursor miRNA (pre-miRNA)," explains corresponding and senior author Akiko Hata, PhD, assistant professor at Tufts University School of Medicine and a member of the biochemistry program faculty at the Sackler School of Graduate Biomedical Sciences. "Smad proteins move to the nucleus of the cell and interact with a specific complex, called the Drosha microprocessor complex, to promote the processing of pri-miR-21 to pre-miR-21, eventually leading to an increase in mature miR-21 levels."

"Mature miR-21 targets a tumor suppressor gene important for programmed cell death in both cancer cells and in smooth muscle cells, the cells that help our veins and arteries contract and relax," contextualizes Brandi Davis, first author, and PhD candidate in the department of biochemistry at Tufts University School of Medicine. "Abnormal miRNA processing is a contributing factor in cardiovascular disorders and cancer, yet little is known about its regulation."

Hata, Davis and colleagues designed a series of experiments to determine how members of a super-family of growth factors, called the transforming growth factor β (TGFβ) family, which is a group of proteins that help regulate cellular functions, can cause miRNA levels to increase. By exposing cells to members of the TGFβ family, the researchers were able to observe that, over time, levels of pre-miR-21 and mature miR-21 increased, while levels of pri-miR-21 did not change. "Since pri-miR-21 levels did not change, we concluded that the TGFβ family of growth factors doesn't begin to play a role in miRNA processing until the pri-miRNA to pre-miRNA step," explains Hata, who is also an investigator in the Molecular Cardiology Research Institute (MCRI) at Tufts Medical Center.

"Smad proteins were thought to act exclusively by regulating the transcription of DNA into messenger RNA (mRNA) in response to TGFβ signaling. This finding reveals a new role of Smad proteins as regulators of miRNA processing," comments Giorgio Lagna, PhD, co-author, investigator in the MCRI at Tufts Medical Center and also an assistant professor at Tufts University School of Medicine. "If we want to generate a drug that regulates signaling by TGFβ, we now have the option to target different pathways downstream of TGFβ and achieve much more specific outcomes."

MiRNAs are small gene products that regulate gene expression by interaction with mRNA. The role of mRNA in a cell is to carry the instructions for making proteins from the DNA in the nucleus to another part of the cell where the instructions are carried out and the proteins are made. "Thus, cells with abnormal miRNA levels may have abnormal protein levels, putting the organism at risk for many diseases including cancer and cardiovascular disorders. More research needs to be done to elucidate further the roles of miR-21 and other miRNA molecules," explains Hata "because better understanding of how miRNAs effect disease may lead to a clearer understanding of disease initiation and progression."


'/>"/>

Contact: Siobhan Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Related medicine news :

1. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
2. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
3. Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
4. 2 microRNAs promote spread of tumor cells
5. MicroRNAs May Predict Colon Cancer Prognosis
6. Single microRNA fine-tunes innate immune response
7. Replacing absent microRNAs could make tumors less invasive, more treatable
8. MicroRNAs, EMT and cancer progression
9. MicroRNAs appear essential for retinal health
10. MicroRNA controls expression of oncogenes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... (PRWEB) , ... April 30, 2017 , ... PracticeMatch, a ... increase in projected attendance for this year’s physician career fairs, with this year’s RSVPs ... complete schedule for the 2017 calendar year of national physician career fairs is located ...
(Date:4/29/2017)... S.C. (PRWEB) , ... April ... ... Southeast’s leading software and web development company, today announced the launch of ... DonorBridge is a solution combining decades of software innovation and industry expertise ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/29/2017)... ... April 29, 2017 , ... Sterling Global Products ... fine retailers selling biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs ... in San Antonio, Texas, operates more than 350 stores throughout Texas and expanding ...
(Date:4/29/2017)... ... April 29, 2017 , ... ... and recognize the positive impact veterinarians have on animal health and welfare as ... Organization for Animal Health (OIE) choose a theme each year and this year ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a ... called the Horizon at PEGS 2017 in ... analyzes sub visible particulate matter in biopharmaceutical samples to ... early as candidate selection and pre-formulation. Halo ... organization Elion Labs for system validation. "We ...
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
Breaking Medicine Technology: